Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus to everolimus conversion after kidney transplantation
NL-OMON36311Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus and tacrolimus in kidney transplant and Renal Insufficiency (RI) (2 arms), sponsored by Erasmus MC. Primary endpoints: Renal function at month 12 and Change in renal function from month 3 to month 12. Started Feb 2011; status: recruiting.
02
Drugs
everolimustacrolimus
03
Conditions
kidney transplantRenal Insufficiency (RI)
Beyond the preview
Go deeper on NL-OMON36311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36311.